Expertise in
12
conditions

Dr. Jason J. Luke

Oncology
UPMC Presbyterian
200 Lothrop St, 
Pittsburgh, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
12
conditions
UPMC Presbyterian
200 Lothrop St, 
Pittsburgh, PA 

Overview

Jason Luke is an Oncologist practicing medicine in Pittsburgh, Pennsylvania.

Dr. Luke is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, and Liver Embolization.

He is actively involved in clinical research, co-authoring 237 peer reviewed articles and participating in 49 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 3 Less Insurance Carriers -

Locations

UPMC Presbyterian
200 Lothrop St, Pittsburgh, PA 15213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

48 Clinical Trials

A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
Enrollment Status: Recruiting
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drugs: ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor
Study Phase: Phase 1
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Enrollment Status: Completed
Publish Date: August 25, 2026
Intervention Type: Biological, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 20, 2026
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, BMS-986253
Study Phase: Phase 1
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)
An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2026
Intervention Type: Biological
Study Drug: RP1 Genetically-Modified Herpes Simplex Type 1 Virus
Study Phase: Phase 1/Phase 2
A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases
A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Radiation, Procedure, Other, Drug
Study Drug: Trametinib
Study Phase: Phase 1
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
View 9 Less Clinical Trials

237 Total Publications

Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.
Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.
Journal: JAMA network open
Published: February 17, 2026
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Allegheny General Hospital

320 E North Ave, 
Pittsburgh, PA 
 (2.5 miles away)
412-359-6391
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nathan Bahary is an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Bahary is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Office

5150 Centre Ave, 
Pittsburgh, PA 
 (1.3 miles away)
412-692-4724
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leonard Appleman is an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Appleman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, and Nephrectomy.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required
Before you request

UPMC Magee-Womens Gynecologic Oncology

300 Halket Street, 
Pittsburgh, PA 
 (0.4 miles away)
412-530-6613
Languages Spoken:
English, Thai
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Sukumvanich is a specialized surgeon and gynecologic oncologist, specializing in the treatment of gynecologic and breast cancers. He serves as an assistant professor in the School of Medicine, and his research centers on the genetic causes of ovarian and breast cancers, and also cancer informatics (the science of analyzing large amounts of information). Dr. Sukumvanich is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Vaginal Cancer, Vulvar Cancer, Vulvectomy, and Lymphadenectomy. Dr. Sukumvanich is board certified in American Board Of Obstetrics And Gynecology and American Board Of Obstetrics And Gynecology. Dr. Sukumvanich is currently accepting new patients.

Frequently Asked Questions about Dr. Jason J. Luke

How do I make an appointment with Dr. Jason J. Luke?

You can book an appointment with Dr. Jason J. Luke by calling their office at 412-383-1370. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jason J. Luke a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jason J. Luke is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jason J. Luke specialize in?

While Dr. Jason J. Luke is a Oncology, they have specific expertise in Melanoma, Metastatic Uveal Melanoma, and Uveal Melanoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jason J. Luke participate in research or clinical trials?

Yes. Dr. Jason J. Luke has published 237 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Jason J. Luke's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jason J. Luke accept my insurance?

Dr. Jason J. Luke accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 412-383-1370 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Luke's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 71 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile